News | August 11, 2024
Merck inks MoU with Aragen to facilitate supply of equipment and technologies for mAb
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Subscribe To Our Newsletter & Stay Updated
